Results 1 to 10 of about 45,688 (235)
Advanced Science, 2021 Fibroblast growth factor receptor 2 (FGFR2) is a membrane‐spanning tyrosine kinase that mediates FGF signaling. Various FGFR2 alterations are detected in breast cancer, yet it remains unclear if activation of FGFR2 signaling initiates tumor formation. In
Josh Lei, Mi-Hye Lee, Kai Miao
exaly +2 more sources
2H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as novel selective fibroblast growth factor receptor 2 (FGFR2) inhibitors [PDF]
Journal of Enzyme Inhibition and Medicinal ChemistryAlthough FGFR2 is a well-validated oncogenic target, no selective FGFR2 inhibitors have been approved for clinical use. In this study, we report the discovery of 2H-pyrazolo[3,4-d]pyrimidin-4-amine derivative as novel, irreversible FGFR2 inhibitors.
Pinglian Wu +11 more
doaj +2 more sources
Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer [PDF]
eLifeFibroblast growth factor receptor 2 (FGFR2) is an important member of receptor tyrosine kinase (RTK) family. FGFR2 amplification occurs at a high frequency in gastric cancer (GC) and has been proven to be closely associated with poor prognosis and ...
Yue Zhang +8 more
doaj +2 more sources
Genomic complexity in advanced gastric and esophageal adenocarcinomas: a case report of rare WDR11-AS1-FGFR2 fusions [PDF]
Frontiers in OncologyFibroblast growth factor receptor 2 (FGFR2) alterations represent an emerging therapeutic target in gastroesophageal adenocarcinoma (GEA). Although FGFR2 amplifications and overexpression have been associated with poor prognosis and therapeutic ...
Eric Mehlhaff +9 more
doaj +2 more sources
Lower FGFR2 mRNA Expression and Higher Levels of FGFR2 IIIc in HER2-Positive Breast Cancer
BiologyFibroblast growth factor receptor 2 (FGFR2) has been associated with breast cancer. We performed in silico analyses to investigate the FGFR2 mRNA expression and splice variants associated with breast cancer subtypes.
Thérèse Dix-Peek +3 more
doaj +3 more sources
The Role of FGFR2 as a Novel Biomarker for Treatment of Gastric Cancer—A Literature Review [PDF]
MedicinaBackground: Gastric cancer currently has the third highest mortality rate worldwide among cancer types. Despite gradual declines in mortality rates attributed to improvements in early detection and treatment, outcomes for advanced-stage disease are still
João Lages dos Santos +2 more
doaj +2 more sources
FGFR2 Inhibition in Cholangiocarcinoma
Annual Review of Medicine, 2023 Biliary tract cancer (BTC) is the second most common primary liver cancer after hepatocellular carcinoma and accounts for 2% of cancer-related deaths. BTCs are classified according to their anatomical origin into intrahepatic (iCCA), perihilar, or distal cholangiocarcinoma, as well as gall bladder carcinoma.
Arndt, Vogel +3 more
openaire +2 more sources
Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas
Cell & Bioscience, 2023 Background Except for gene fusions, FGFR2 genetic alterations in intrahepatic cholangiocarcinomas (ICCs) have received limited attention, leaving patients harboring activating FGFR2 gene mutations with inadequate access to targeted therapies ...
Xiaohong Pu +11 more
doaj +1 more source
PLoS ONE, 2022 The significance of fibroblast growth factor receptor 2 (FGFR2) in gastric cancer (GC) has been studied predominantly in Asian patient cohorts. Data on White patients are scarce.
Thorben Schrumpf +4 more
doaj +2 more sources
生物医学转化, 2021 Apert syndrome (AS) is characterized by synostosis of coronal sutures, midfacial hypoplasia,abnormity of brain, syndactyly of hands and feet. Majority of AS is caused by gain-of-function mutation of fibro‐blast growth factor receptor 2 (FGFR2).
Luo Fengtao +5 more
doaj +1 more source